One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin

Published:2016-08-19 Issue:11 Volume:18 Page:1128-1133
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Matthaei S.¹,Aggarwal N.²,Garcia-Hernandez P.³,Iqbal N.⁴,Chen H.⁴,Johnsson E.⁵,Chin A.⁴,Hansen L.⁶

Affiliation:

1. Diabetes-Zentrum; Quakenbrück Hospital; Quakenbrück Germany

2. Aggarwal and Associates, Ltd; Brampton Ontario Canada

3. Servicio de Endocrinologia; Hospital Universitario Dr. José Eleuterio Gonzalez; Monterrey Nuevo Leon Mexico

4. Global Medicines Development; AstraZeneca; Gaithersburg Maryland USA

5. Global Medicines Development; AstraZeneca; Gothenburg Sweden

6. Global Clinical Research Metabolics; Bristol-Myers Squibb; Princeton New Jersey USA

Funder

Bristol-Myers Squibb

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12741/fullpdf

Reference21 articles.

1. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015;Handelsman;Endocr Pract,2015

2. Review of current and emerging therapies in type 2 diabetes mellitus;Mazzola;Am J Manag Care,2012

3. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1;Nauck;Diabetologia,2005

4. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes;Nauck;Drug Des Devel Ther,2014

5. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2016 Executive Summary;Garber;Endocr Pract,2016

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings;Journal of Endocrinology and Metabolism;2024-06

2. Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study;Diabetes & Metabolism;2023-07

3. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION);Endocrinology and Metabolism;2023-06-30

4. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use;Pharmacy & Pharmacology;2023-04-28

5. Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy;Diabetes, Obesity and Metabolism;2021-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3